Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03954626 · ClinicalTrials.gov registry record · Phase 3
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
A Phase 3 study of Age-related Macular Degeneration and Eye Diseases, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 14
- Enrollment target
- 3
- Study locations
NCT03954626 is a Phase 3 study of Age-related Macular Degeneration and Eye Diseases that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 14 participants, below the 1,508-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03954626, a Phase 3 study of Age-related Macular Degeneration and Eye Diseases, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 14 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study was to collect ECG data after a single IVT injection of brolucizumab 6 mg in patients with neovascular age-related macular degeneration (nAMD).
Conditions Studied
Interventions
- BIOLOGICAL brolucuzumab 6 mg IVT
Study Locations (3)
Arizona
- Novartis Investigative Site - Phoenix
Texas
- Novartis Investigative Site - Abilene
Other
- Novartis Investigative Site - Arecibo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-06-07 |
| Est. Completion | 2019-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03954626
The ClinicalTrials.gov registry entry for NCT03954626 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,508-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (99% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which brolucuzumab 6 mg IVT is the first listed.
NCT03954626 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT03954626 about?
NCT03954626 is a clinical study titled "Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD". The purpose of this study was to collect ECG data after a single IVT injection of brolucizumab 6 mg in patients with neovascular age-related macular degeneration (nAMD).
What is the current status of trial NCT03954626?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 14 participants. The study started on 2019-06-07. Estimated completion is 2019-07-31.
What conditions does trial NCT03954626 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration, Eye Diseases, Macular Degeneration, Retinal Degeneration, Retinal Diseases.
What interventions are being tested in trial NCT03954626?
The interventions under investigation include: brolucuzumab 6 mg IVT (BIOLOGICAL).
Who is sponsoring clinical trial NCT03954626?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03954626 being conducted?
This trial has 3 study locations across Arizona, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
ACTIVE NOT RECRUITING · Phase 3
-
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
COMPLETED · Phase 3
-
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
COMPLETED · Phase 3
-
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
COMPLETED · Phase 3
-
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
COMPLETED · Phase 3
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.